81MO Survival and safety of tinengotinib in pooled patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma (CCA)
Year: 2025
Type: article
Source: Annals of Oncology
Authors: M. Javle, C-Y.A. Liao, L. Shen, L.A. Kankeu Fonkoua, C. Fountzilas, D. Li, M. Pelster, B. Cao, D. Deming, F. Dayyani, P. Huang, Y. Zhu, H. Wang, X. Du, L. Neo, K. Hennessy, C.A. Sun, F. Wu, J. Fan, S.A. Piha-Paul
Institutions: The University of Texas MD Anderson Cancer Center, University of Chicago, Peking University Cancer Hospital, Mayo Clinic, Roswell Park Comprehensive Cancer Center, City Of Hope National Medical Center, City of Hope, Sarah Cannon, Peking University Third Hospital, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, University of California, Irvine
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415941107